ReviewACS pharmacology & translational science2026
Heparanase, Endothelial Dysfunction, and Cardiovascular Risk: The Emerging Role of Vitamin D.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial dysfunction is a central pathophysiological mechanism in the development of cardiovascular disease (CVD), the leading global cause of morbidity and mortality. Vascular homeostasis critically depends on the endothelial glycocalyx, which regulates vascular permeability, mechanotransduction, and anti-inflammatory signaling. Heparanase, the only known mammalian endoglycosidase capable of cleaving heparan sulfate, plays a pivotal role in glycocalyx degradation, a process exacerbated by oxidative stress, hyperglycemia, and hypertension. Excessive heparanase activity has been implicated in several cardiovascular pathologies, including heart failure, ischemia-reperfusion injury, and atherosclerosis, yet effective therapeutic strategies remain limited. Emerging evidence suggests that vitamin D may preserve endothelial integrity by maintaining the structure of the glycocalyx and suppressing heparanase expression, as demonstrated in podocytes. By attenuating heparanase-mediated degradation of the glycocalyx in the vasculature and heart, vitamin D could exert protective effects against endothelial dysfunction and thereby mitigate cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.